Comparing of Magenta Therapeutics Inc. (MGTA) and Melinta Therapeutics Inc. (NASDAQ:MLNT)

Magenta Therapeutics Inc. (NASDAQ:MGTA) and Melinta Therapeutics Inc. (NASDAQ:MLNT), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Magenta Therapeutics Inc. N/A 0.00 57.60M -4.62 0.00
Melinta Therapeutics Inc. 96.43M 0.53 157.19M -21.57 0.00

In table 1 we can see Magenta Therapeutics Inc. and Melinta Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 has Magenta Therapeutics Inc. and Melinta Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Magenta Therapeutics Inc. 0.00% 0% 0%
Melinta Therapeutics Inc. -163.01% -69.8% -33.4%


Magenta Therapeutics Inc. has a Current Ratio of 13.7 and a Quick Ratio of 13.7. Competitively, Melinta Therapeutics Inc.’s Current Ratio is 1.3 and has 1 Quick Ratio. Magenta Therapeutics Inc.’s better ability to pay short and long-term obligations than Melinta Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for Magenta Therapeutics Inc. and Melinta Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Magenta Therapeutics Inc. 0 1 0 2.00
Melinta Therapeutics Inc. 0 0 0 0.00

The consensus target price of Magenta Therapeutics Inc. is $16, with potential upside of 1.59%.

Institutional & Insider Ownership

Roughly 56.5% of Magenta Therapeutics Inc. shares are held by institutional investors while 61.9% of Melinta Therapeutics Inc. are owned by institutional investors. 14.76% are Magenta Therapeutics Inc.’s share held by insiders. Insiders Comparatively, held 8.4% of Melinta Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Magenta Therapeutics Inc. 48.38% 122.68% 73.25% 8.03% 0% 173.86%
Melinta Therapeutics Inc. -13.45% 22.01% -55.22% -77.61% -92.23% 29.94%

For the past year Magenta Therapeutics Inc.’s stock price has bigger growth than Melinta Therapeutics Inc.


On 8 of the 10 factors Magenta Therapeutics Inc. beats Melinta Therapeutics Inc.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.